These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1633300)

  • 21. Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443.
    Hullett DA; Landry AS; Eckoff DE; Nichols JC; Eugui EM; Allison AC; Sollinger HW
    Transpl Int; 1992; 5 Suppl 1():S487-9. PubMed ID: 14621855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
    Foss FM
    Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-2-diphtheria toxin fusion protein prolongs murine islet cell engraftment.
    Pankewycz O; Mackie J; Hassarjian R; Murphy JR; Strom TB; Kelley VE
    Transplantation; 1989 Feb; 47(2):318-22. PubMed ID: 2493178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of cytokine transcripts in pancreatic islet cell allografts during rejection and tolerance induction.
    Nickerson P; Pacheco-Silva A; O'Connell PJ; Steurer W; Kelley VR; Strom TB
    Transplant Proc; 1993 Feb; 25(1 Pt 2):984-5. PubMed ID: 8442291
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical trials of targeted toxins.
    Frankel AE; Tagge EP; Willingham MC
    Semin Cancer Biol; 1995 Oct; 6(5):307-17. PubMed ID: 8562908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotoxins and recombinant toxins for cancer treatment.
    Pai LH; Pastan I
    Important Adv Oncol; 1994; ():3-19. PubMed ID: 8206493
    [No Abstract]   [Full Text] [Related]  

  • 27. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
    Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
    J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The interleukin-2 receptor: a target for immunotherapy.
    Waldmann TA; Goldman C; Top L; Grant A; Burton J; Bamford R; Roessler E; Horak I; Zaknoen S; Kasten-Sportes C
    Adv Exp Med Biol; 1992; 323():57-66. PubMed ID: 1485565
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunotherapy using interleukin-2 diphtheria toxin chimer prolongs murine allografts.
    Mackie JD; Pankewycz OG; Hassarjian R; Murphy JR; Kelley VE; Strom TB
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2718-9. PubMed ID: 2495680
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of recombinant interleukin-2 in therapy for hematologic malignancies.
    Dutcher JP; Wiernik PH
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):33-40. PubMed ID: 8284690
    [No Abstract]   [Full Text] [Related]  

  • 33. [An expression plasmid encoding recombinant immunotoxin IP10-DT390 suppresses the experimental autoimmune encephalomyelitis].
    Chen W; Li H; Jia Y; Li M; Jiang Z; Lü M; Zhang L
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Oct; 24(5):1118-22. PubMed ID: 18027709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric fusion proteins--Pseudomonas exotoxin-based.
    Kreitman RJ
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diphtheria toxin conjugate therapy of cancer.
    Frankel AE; Powell BL; Lilly MB
    Cancer Chemother Biol Response Modif; 2002; 20():301-13. PubMed ID: 12703211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric fusion proteins--diphtheria toxin-based.
    Frankel AE; Powell BL; Vallera DA; Neville DM
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1294-301. PubMed ID: 11717818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide toxins directed at the matrix dissolution systems of cancer cells.
    Frankel AE; Bugge TH; Liu S; Vallera DA; Leppla SH
    Protein Pept Lett; 2002 Feb; 9(1):1-14. PubMed ID: 12141918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells.
    Arora N; Masood R; Zheng T; Cai J; Smith DL; Gill PS
    Cancer Res; 1999 Jan; 59(1):183-8. PubMed ID: 9892205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant fusion toxins directed against the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor.
    Shao Y; Warman BE; Perentesis JP
    Methods Mol Biol; 2001; 166():31-53. PubMed ID: 11217375
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.